AstraZeneca Ovarian-Cancer Drug Wins EU Agency’s Backing
This article is for subscribers only.
AstraZeneca Plc won backing from a European Union regulator for an ovarian-cancer drug, one of the experimental medicines the company cited as a reason for fending off Pfizer Inc.’s $117 billion takeover offer this year.
The treatment, olaparib, should receive a marketing authorization for use in patients with a mutation in one of two genes called BRCA, the European Medicines Agency’s Committee for Medicinal Products for Human Use said in a statement today. The European Commission usually follows the committee’s recommendation. The drug will be marketed under the name Lynparza.